Do all patients with hematologic malignancies and severe thrombocytopenia need prophylactic platelet transfusions?: Background, rationale, and design of a clinical trial (trial of platelet prophylaxis) to assess the effectiveness of prophylactic platelet Transfusions

Transfusion Medicine Reviews

Volumn 24, Issue 3, 2010, Pages 163-171

  Stanworth, Simon J ^{a,b,c,d,e,f,g}   Dyer, Claire ^{a,b,c,d,e,f,g}   Choo, Louise ^{a,b,c,d,e,f,g}   Bakrania, Lekha ^{a,b,c,d,e,f,g}   Copplestone, Adrian ^{a,b,c,d,e,f,g}   Llewelyn, Charlotte ^{a,b,c,d,e,f,g}   Norfolk, Derek ^{a,b,c,d,e,f,g}   Powter, Gillian ^{a,b,c,d,e,f,g}   Littlewood, Tim ^{a,b,c,d,e,f,g}   Wood, Erica M ^{a,b,c,d,e,f,g}   Murphy, Mike F ^{a,b,c,d,e,f,g}  

^a NHS BLOOD AND TRANSPLANT   (United Kingdom)

^b UNIVERSITY OF OXFORD   (United Kingdom)

^c MRC CLINICAL TRIALS UNIT   (United Kingdom)

^d DERRIFORD HOSPITAL   (United Kingdom)

^e LEEDS GENERAL INFIRMARY   (United Kingdom)

^f OXFORD UNIVERSITY HOSPITALS NHS FOUNDATION TRUST   (United Kingdom)

^g AUSTRALIAN RED CROSS BLOOD SERVICE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; BLEEDING; BONE MARROW SUPPRESSION; CLINICAL TRIAL; HEMATOLOGIC DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; OUTCOME ASSESSMENT; PROPHYLAXIS; THROMBOCYTE COUNT; THROMBOCYTE TRANSFUSION; THROMBOCYTOPENIA; UNITED KINGDOM; WORLD HEALTH ORGANIZATION; CLINICAL PROTOCOL; COMPLICATION; HEMATOLOGIC NEOPLASMS; HEMORRHAGE; PROCEDURES; RANDOMIZED CONTROLLED TRIAL (TOPIC);

CLINICAL PROTOCOLS; HEMATOLOGIC NEOPLASMS; HEMORRHAGE; HUMANS; OUTCOME ASSESSMENT (HEALTH CARE); PLATELET TRANSFUSION; RANDOMIZED CONTROLLED TRIALS AS TOPIC; THROMBOCYTOPENIA;

EID: 77955118356     PISSN: 08877963     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.tmrv.2009.11.002     Document Type: Article

References (37)

1. Qureshi H., Lowe D., Dobson P., et al. National comparative audit of the use of platelet transfusions in the UK. Transfus Clin Biol 2007, 14:509-513.
2. Eikenboom J.C., van Wordragen R., Brand A. Compliance with prophylactic platelet transfusion trigger in hematological patients. Transfus Med 2005, 15:45-48.
3. Blajchman M.A., Slichter S.J., Heddle N.M., et al. New strategies for the optimal use of platelet transfusions. Hematology Am Soc Hematol: Educ Program 2008, 198-204.
4. Corash L. How much do we know about the platelet transfusion threshold?. Transfusion 2003, 43:691-693.
5. Schiffer C.A., Anderson K.C., Bennett C.L., et al. Platelet transfusion for patients with cancer: Clinical practice guidelines of the American Society of Clinical Oncology. J Clin Oncol 2001, 19:1519-1538.
6. Solomon J., Bofenkamp T., Fahey J.L., et al. Platelet prophylaxis in acute non-lymphoblastic leukaemia. Lancet 1978, 1:267.
7. Higby D.J., Cohen E., Holland J.F., et al. The prophylactic treatment of thrombocytopenic leukemic patients with platelets: A double blind study. Transfusion 1974, 14:440-446.
8. Murphy S., Litwin S., Herring L.M., et al. Indications for platelet transfusion in children with acute leukemia. Am J Hematol 1982, 12:347-356.
9. Friedmann A.M., Sengul H., Lehmann H., et al. Do basic laboratory tests or clinical observations predict bleeding in thrombocytopenic oncology patients?. Transfus Med Rev 2002, 16:34-45.
10. Goerge T., Ho-Tin-Noe B., Carbo C., et al. Inflammation induces hemorrhage in thrombocytopenia. Blood 2008, 111:4958-4964.
11. Slichter S.J. Relationship between platelet count and bleeding risk in thrombocytopenic patients. Transfus Med Rev 2004, 18:153-167.
12. Wandt H., Reinel H., Schaefer-Eckart K., et al. New strategy for platelet transfusion for patients with acute myeloid leukaemia: Routine prophylactic transfusion replaced by therapeutic transfusion. Blood 2002, 100(suppl):706a, 2002. (abstr).
13. Wandt H., Wendelin K., Schaefer-Eckart K., et al. A therapeutic platelet transfusion strategy without routine prophylactic transfusion is feasible and safe and reduces platelet transfusion numbers significantly: Preliminary analysis of a randomized study in patients after high dose chemotherapy and autologous peripheral blood stem cell transplantation. Blood 2008, 112(suppl):112, 2002. (abstr 286).
14. Wandt H., Schaefer-Eckart K., Frank M., et al. A therapeutic platelet transfusion strategy is safe and feasible in patients after autologous peripheral blood stem cell transplantation. Bone Marrow Transplant 2006, 37:387-392.
15. Kleinman S., Chan P., Robillard P. Risks associated with transfusion of cellular blood components in Canada. Transfus Med Rev 2003, 17:120-162.
16. Stainsby D., Jones H., Asher D., et al. Serious hazards of transfusion: A decade of hemovigilance in the UK. Transfus Med Rev 2006, 20:273-282. on behalf of the SHOT Steering Group.
17. 9/L trigger: A prospective comparative trial in 105 patients with acute myeloid leukaemia. Blood 1998, 91:3601-3606.
18. Stanworth S.J., Dyer C., Casbard A., et al. Feasibility and usefulness of self-assessment of bleeding in patients with hematological malignancies, and the association between platelet count and bleeding. Vox Sang 2006, 91:63-69.
19. Denne J.S. Sample size recalculation using conditional power. Stat Med 2001, 20:2645-2660.
20. Gould A.L. Sample size re-estimation: Recent developments and practical considerations. Stat Med 2001, 20:2625-2643.
21. BCSH Guidelines on Platelet transfusions. Br J Haematol 2003, 122:10-23.
22. BCSH red cell transfusion. Br J Haematol 2001, 113:24-31.
23. http://www.transfusion.com.au//NHMRC-ANZSBT-Guidelines.
24. Heddle N.M., Cook R.J., Tinmouth A., et al. A randomized controlled trial comparing standard and low dose strategies for transfusion of platelets (SToP) to patients with thrombocytopenia. Blood 2009, 113:1564-1573.
25. Taylor C (ed), Cohen H, Mold D, et al, on behalf of the Serious Hazards of Transfusion (SHOT) Steering Group. The 2008 Annual SHOT Report, 2009.
26. Kato T., Matsumoto A., Ogami K., et al. Native thrombopoietin: Structure and function. Stem Cells 1998, 16:322-328.
27. Synopsis of background papers and consensus statement. Br J Haematol 1998, 101:609-617. Consensus Conference on Platelet Transfusion.
28. Rebulla P., Finazzi G., Marangoni F., et al. The threshold for prophylactic platelet transfusions in adults with acute myeloid leukaemia. N Engl J Med 1997, 337:1870-1875.
29. Stanworth S.J., Hyde C., Heddle N., et al. Prophylactic platelet transfusion for haemorrhage after chemotherapy and stem cell transplantation. The Cochrane Library, Issue 1 2004, John Wiley & Sons, Ltd, Chichester, UK.
30. Zumberg M.S., del Rosario M.L., Nejame C.F., et al. A prospective randomized trial of prophylactic platelet transfusion and bleeding incidence in haemopoietic stem cell transplant recipients: 10,000/microL versus 20,000/microL trigger. Biol Blood Marrow Transplant 2002, 8:569-576.
31. Tinmouth A.T., Freedman J. Prophylactic platelet transfusions: which dose is the best dose? A review of the literature. Transfus Med Rev 2003, 17:181-193.
32. Slichter S.J. Background, rationale and design of a clinical trial to assess the effects of platelet dose on bleeding risk in thrombocytopenic patients. J Clin Apher 2006, 21:78-84.
33. Slichter S.J., Kaufman R.M., Assmann S.F., et al. Effects of prophylactic platelet (Plt) dose on transfusion (Tx) outcomes (PLADO Trial). Blood 2008, 112(suppl):111-112. (abstr 285).
34. Cook R.J., Heddle N.M., Rebulla P., et al. Methods for the analysis of bleeding outcomes in randomized trials of PLT transfusion triggers. Transfusion 2004, 44:1135-1142.
35. Heddle N.M., Cook R.J., Webert K.E., et al. Methodologic issues in the use of bleeding as an outcome in transfusion medicine studies. Transfusion 2003, 43:742-752.
36. Miller A.B., Hoogsraten B., Staquet M., et al. Reporting results of cancer treatment. Cancer 1981, 47:207-209.
37. Webert K., Cook R.J., Sigouin C.S., et al. The risk of bleeding in thrombocytopenic patients with acute myeloid leukemia. Haematologica 2006, 91:1530-1537.